Roger Dansey
About Roger Dansey
Roger Dansey, M.D., was appointed as an independent Class III director of Bicycle Therapeutics (BCYC) effective September 8, 2025; he serves on the Scientific Committee and the Nominating & Corporate Governance Committee and entered the company’s standard deed of indemnity upon appointment . He is a seasoned oncology drug developer, previously interim chief oncology officer and chief development officer at Pfizer Oncology, chief medical officer and president of R&D at Seagen, with senior leadership roles at Merck, Gilead Sciences, and Amgen; he earned his M.D. from the University of Witwatersrand and was an associate professor of hematology/oncology at the Karmanos Cancer Institute . His service term runs through the 2028 annual general meeting, and the Board has determined he meets Nasdaq independence standards; there are no Item 404(a) related-party transactions or family relationships reported . Bicycle has director share ownership guidelines (3x annual cash retainer within 5 years) implemented in December 2024 to reinforce alignment .
Past Roles
| Organization | Role | Tenure/Years | Committees/Impact |
|---|---|---|---|
| Pfizer Oncology | Interim Chief Oncology Officer; Chief Development Officer | Not disclosed | Led development/approvals of oncology assets |
| Seagen | Chief Medical Officer; President of Research & Development | Not disclosed | Key role in ADC portfolio including Adcetris/Padcev/Tivdak |
| Merck | Senior leadership positions | Not disclosed | Contributed to Keytruda development |
| Gilead Sciences | Senior leadership positions | Not disclosed | Contributed to Zydelig |
| Amgen | Senior leadership positions | Not disclosed | Contributed to Xgeva/Prolia |
| Karmanos Cancer Institute | Associate Professor, Hematology/Oncology | Not disclosed | Academic clinical leadership |
External Roles
| Organization | Role | Start (as disclosed) | Notes |
|---|---|---|---|
| Inovio Inc. | Director | As of Sept 2025 | Current public company board |
| Ottimo Pharma | Director | As of Sept 2025 | Current public company board |
Board Governance
- Independent director; Class III term through the 2028 AGM; committees: Scientific Committee and Nominating & Corporate Governance Committee .
- Entered Bicycle’s standard director deed of indemnity upon appointment .
- Non-employee director compensation policy specifies annual cash fees and equity grants; RSUs may be deferred at Compensation Committee discretion .
- Director share ownership guidelines: non-employee directors expected to own shares valued at least three times annual cash retainer within five years; options and unearned performance RSUs do not count toward compliance .
Fixed Compensation
| Fee Component (2025 policy) | Amount (USD) | Basis |
|---|---|---|
| Board Member Annual Cash Fee | $50,000 | Non-Employee Director Compensation Policy |
| Scientific Committee Member | $10,000 | Non-Employee Director Compensation Policy |
| Nominating & Corporate Governance Committee Member | $10,000 | Non-Employee Director Compensation Policy |
Policy update effective January 1, 2025 increased initial and annual equity grant sizes; cash fee schedule for 2025 shown above .
Performance Compensation
| Award Type | Grant Date | Shares/Units | Strike Price | Expiration | Vesting Schedule |
|---|---|---|---|---|---|
| RSU | 09/08/2025 | 12,500 | n/a | n/a | 1/3 each on 09/08/2026, 09/08/2027, 09/08/2028 |
| Stock Option | 09/08/2025 | 25,000 | $7.16 | 09/08/2035 | 1/3 each on 09/08/2026, 09/08/2027, 09/08/2028 |
| Performance Conditions | Detail |
|---|---|
| None | Director and CEO awards have no performance-based conditions; vesting is time-based . |
Other Directorships & Interlocks
| Company | Relationship to BCYC | Potential Conflict Assessment |
|---|---|---|
| Inovio Inc.; Ottimo Pharma | External public boards | Board determined no Item 404(a) related-party transactions; no family relationships disclosed . |
Expertise & Qualifications
- Oncology drug development leader credited with contributions to approvals for Keytruda, Xgeva/Prolia, Zydelig, Adcetris, Padcev, Tivdak, and Tukysa, indicating deep regulatory and clinical execution experience .
- M.D. from University of Witwatersrand; prior academic role in hematology/oncology; broad biopharma leadership experience across Pfizer, Seagen, Merck, Gilead, and Amgen .
Equity Ownership
| Instrument | Status | Quantity | Ownership Form | Notes |
|---|---|---|---|---|
| RSUs | Unvested, time-based | 12,500 | Direct | Vests in three equal annual tranches starting 09/08/2026 |
| Stock Options | Unexercisable until vest dates | 25,000 | Direct | $7.16 strike; expire 09/08/2035; vests in three equal annual tranches starting 09/08/2026 |
| Ownership Guidelines | Policy | 3x annual cash retainer; 5-year deadline; options excluded | n/a | Implemented Dec 2024; overseen by Compensation Committee |
Total potential share issuance from awards = 37,500 (12,500 RSUs + 25,000 option shares), subject to vesting and exercise .
Insider Filings
| Filing | Date Filed | Event Date | Key Details |
|---|---|---|---|
| Form 3 | 09/10/2025 | 09/08/2025 | Initial statement of beneficial ownership; POA included |
| Form 4 | 09/10/2025 | 09/08/2025 | 12,500 RSUs; 25,000 options at $7.16, vest annually (2026–2028), option expires 09/08/2035 |
Governance Assessment
- Board effectiveness signal: Adds top-tier oncology development and approval experience (Keytruda/ADC programs), strengthening Scientific and NomGov oversight in a pipeline-heavy phase .
- Independence and conflicts: Board affirmed independence; 8-K confirms no Item 404(a) related-party transactions or family relationships—low conflict risk .
- Compensation and alignment: Mix of modest cash fees ($50k board + committee fees per policy) and time-based RSUs/options under the updated 2025 policy; RSUs may be deferred; director equity awards are not performance-based, typical for NEDs but less tied to explicit metrics .
- Ownership alignment: Director share ownership guidelines (3x cash retainer within 5 years) and anti-hedging/anti-pledging framework noted by the Board enhance alignment, with options excluded from compliance calculations .
- Dilution awareness: Initial RSU/option grants represent up to 37,500 shares if fully vested and exercised, a standard scale for BCYC directors under 2025 policy .
No RED FLAGS identified: no related-party transactions, no gross-up/perquisite disclosures tied to Dansey, and equity awards follow standard director policy with time-based vesting .